Alex Sparreboom, PhD
Professor
Pharmaceutics and Pharmacology
Outcomes and Translational Sciences
Professional Interests
Dr. Sparreboom's research studies the contribution of solute carriers to chemotherapy-induced toxicity profiles, identifies chemical inhibitors of critical transporters, translates the findings to clinical trials in collaboration with scientists and oncologists, and ultimately improves the long-term outcome of patients with cancer by modulating the therapeutic window of widely-used chemotherapeutics. His research is currently focused on the development of transport modulators that could be used in conjunction with platinum-based drugs and tyrosine-kinase inhibitors, with emphasis on the development of innovative preclinical model systems.
Research Areas:
Education
- PhD, 1996, The Netherlands Cancer Institute/Utrecht University, Pharmacy
- MSc, 1993, Utrecht University, Pharmacy
- BSc, 1989, Utrecht University, Pharmacy
Publications
- Determination and Disposition of the Aromatase Inhibitor Exemestane in CYP3A-Deficient Mice, Molecules. 2025 Mar | journal-article. doi: 10.3390/molecules30071440.
- Itraconazole-Induced Increases in Gilteritinib Exposure Are Mediated by CYP3A and OATP1B, Molecules. 2022 Oct | journal-article. doi: 10.3390/molecules27206815.
- A Metabolomics Approach for Predicting OATP1B-Type Transporter-Mediated Drug–Drug Interaction Liabilities, Pharmaceutics. 2022 Sep | journal-article. doi: 10.3390/pharmaceutics14091933.
- MATE1 Deficiency Exacerbates Dofetilide-Induced Proarrhythmia, International Journal of Molecular Sciences. 2022 Aug | journal-article. doi: 10.3390/ijms23158607.